Raj Parekh, Ph.D.
Raj Parekh is a General Partner of Advent Life Sciences. He joined Advent in 2005, bringing over 20 years of experience in biomedical research and as an entrepreneur and investor. Prior to joining Advent, Raj was a founding Director at Celldex Therapeutics, and before that, he was Chairman of Chroma Therapeutics and of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund. Previously, Raj co-founded Oxford GlycoSciences, which became listed on the LSE and NASDAQ and was later acquired by UCB-Celltech. He began his career in academia, in molecular medicine at the University of Oxford. Raj received a Ph.D., an MA and a BA in Biochemistry and Molecular Medicine, all from the University of Oxford.
Raj has served on the boards of directors of several portfolio companies, including Thiakis, Avila, EUSA and Cellnovo.